Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Ups Private Offering by $100 Million

NEW YORK, Dec. 6 - Invitrogen on Thursday announced that it has increased from $400 million to $500 million its private offering of convertible subordinated notes due 2006.


The company said it plans to use the net for general corporate purposes, including research and development activities and working capital, investments in infrastructure, and potential acquisitions. The transaction is expected to close on Dec. 11.


According to Invitrogen, the notes may be converted at any time into shares of its common stock at a cost of $86.10 per share. The notes, which will accrue 2.25 percent interest per year that will be payable semiannually, will mature in five years and will be callable after Dec. 20.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.